You are here:

apixaban (Eliquis)

Advice

following a full submission:

apixaban (Eliquis®) is accepted for use within NHS Scotland.

Indication under review: for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA class ≥II).

Apixaban was superior to standard oral anticoagulation at preventing stroke or systemic embolism in one large, double-blind study in patients with atrial fibrillation and at least one risk factor for stroke. It was also associated with a significant reduction in risk of major bleeding.
 

Drug Details

Drug Name: apixaban (Eliquis)
SMC Drug ID: 836/13
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: For the prevention of stroke and systemic embolism (SE) in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors such as prior stroke or transient ischaemic attack(TIA): age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYYA Class ≥ II).
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 11 February 2013

Back